Luca Rastelli

USPTO Granted Patents = 16 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 114(Granted Patents)

Location History:

Branford, CT (US) (2006)
Guilford, CT (US) (2002 - 2015)
Norwell, MA (US) (2017 - 2023)
New Haven, CT (US) (2023)

Company Filing History:

Celldex Therapeutics Limited

patents

4. 2 out of 2

Onkosxcel Therapeutics, LLC

Sola Biosciences, LLC

patents

7. 2 out of 832,966

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613785 - Predictive and diagnostic methods for prostate cancer (2023-03-28),

2. 11564986 - Approach for treatment of cancer via immunomodulation by using talabostat (2023-01-31),

3. 9758807 - Protein expression enhancing polypeptides (2017-09-12),

4. 9051615 - Method of detecting and treating tuberous sclerosis complex associated disorders (2015-06-09),

5. 8846873 - Antibodies directed to GPNMB and uses thereof (2014-09-30),

6. 7566536 - WNT-regulated cytokine-like polypeptide and nucleic acids encoding same (2009-07-28),

7. 7141549 - Proteins and nucleic acids encoding same (2006-11-28),

8. 7112668 - Polypeptides and nucleic acids encoded thereby (2006-09-26),

9. 7109000 - Proteins and nucleic acids encoding same (2006-09-19),

10. 7034132 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use (2006-04-25),

11. 7005499 - Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same (2006-02-28),

12. 6991901 - Proteins and nucleic acids encoding same (2006-01-31),

13. 6964849 - Proteins and nucleic acids encoding same (2005-11-15),

14. 6858427 - Sphingosine kinases (2005-02-22),

15. 6653448 - Wnt-7B-like polypeptides and nucleic acids encoding same (2003-11-25),

Title: Innovations and Contributions of Inventor Luca Rastelli

Introduction

Luca Rastelli is a prominent inventor based in Guilford, CT (US), known for his significant contributions to the field of cancer research. With a total of 16 patents to his name, Rastelli has focused on developing innovative methods for diagnosing and treating prostate cancer. His work has the potential to greatly impact patient care and treatment outcomes.

Latest Patents

Rastelli's latest patents include groundbreaking inventions such as predictive and diagnostic methods for prostate cancer. This invention relates to a method of diagnosing, prognosing, and treating patients with castration-resistant prostate cancer (CrPC). It provides a computational approach to identifying potential patients for combination therapy involving a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. Another notable patent is the approach for the treatment of cancer via immunomodulation using Talabostat. This method discloses a way to treat, prevent, or ameliorate tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase, in combination with an immune checkpoint inhibitor.

Career Highlights

Throughout his career, Rastelli has worked with notable companies such as Curagen Corporation and Genentech, Inc. His experience in these organizations has contributed to his expertise in cancer research and development.

Collaborations

Rastelli has collaborated with esteemed colleagues, including John L. Herrmann and John R. MacDougall. These partnerships have fostered innovation and advancement in his research endeavors.

Conclusion

Luca Rastelli's contributions to cancer research through his patents and collaborations highlight his commitment to improving patient outcomes. His innovative approaches in diagnosing and treating prostate cancer are paving the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.